We investigated the influence of a specific serotonin receptor blockade on pituitary hormone secretion in normal cycling women and postmenopausal women not receiving hormone replacement therapy. Serotonin receptor blockade was performed by using the HT-3 receptor subtype antagonist ondansetron as an i.v. bolus injection of 8 mg. Blood samples were taken before as well as 20, 30 and 40 min after ondansetron administration for the estimation of LH, FSH, and TSH. We could not find any hormonal changes in the normal cycling women. The postmenopausal women showed a significant decline in LH secretion, whereas FSH and TSH levels remained unchanged. Our results suggest serotoninergic involvement in LH secretion in postmenopausal hypoestrogenic hypergonadism.

Keywords:
Ondansetron, Serotonin receptor antagonist, Pituitary hormones
1.
Pontiroli AE, Alberetto M, Pellicciotta G, De Castro e Silva E, De Pasqua A, Girardi AM, Pozza G: Interaction of dopaminergic and antiserotoninergic drugs in the control of prolactin and LH release in normal women. Acta Endocrinol (Copenh) 1980;93:271–276.
2.
Ulrich UL, Nowara I, Rossmanith WG: Serotoninergic control of gonadotrophin and prolactin secretion in women. Clin Endocrinol (Oxf) 1994;41:779–785.
3.
Pijl H, Koppeschaar HP, Willekens FL, Frolich M, Meinders AE: The influence of serotonergic neurotransmission on pituitary hormone release in obese and non-obese females. Acta Endocrinol (Copenh) 1993;128:319–324.
4.
Tepavcevic DZ, Giljevic Z, Korsic M, Halimi S, Suchanek E, Jelic T, Aganovic I, Kozic B, Plavsic V: Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans. J Endocrinol Invest 1994;17:1–5.
5.
Coccaro EF, Siever LJ, Kourides IA, Adan F, Campbell G, Davis KL: Central serotoninergic stimulation by fenfluramine challenge does not affect plasma thyrotropin-stimulating hormone levels in man. Neuroendocrinology 1988;47:273–276.
6.
Tyers MB, Bunce KT, Humphrey PP: Pharmacological and anti-emetic properties of ondansetron. Eur J Cancer Clin Oncol 1989;25(suppl 1):S15–19.
7.
Vitale ML, Chiocchio SR: Serotonin, a neurotransmitter involved in the regulation of luteinizing hormone release. Endocr Rev 1993;14:480–493.
8.
Aguilar E, Ranchal A, Aguilar R, Pinilla L: Gonadotropin and prolactin secretion in prepubertal female rats treated with 8-hydroxy-2-(di-n-propylamino) tetralin. J Neural Transm Gen Sect 1993;94:165–173.
9.
Ruzsas C, Limonta P, Martini L: Role of serotoninergic neurones in the control of gonadotropin and prolactin secretion in the rat. J Endocrinol 1982;94:83–89.
10.
Porter JC, Mical RS, Cramer OM: Effect of serotonin and other indoles on the release of LH, FSH, and prolactin. Gynecol Invest 1971;2:13–22.
11.
Donnelly PJ, Dailey RA: Effects of dopamine, norepinephrine and serotonin on secretion of luteinizing hormone, follicle-stimulating hormone and prolactin in ovariectomized, pituitary stalk-transected ewes. Domest Anim Endocrinol 1991;8:87–98.
12.
Vitale ML, Parisi MN, Chiocchio SR, Tramezzani JH: Serotonin induces gonadotrophin release through stimulation of LH-releasing hormone release from the median eminence. J Endocrinol 1986;111:309–315.
13.
Labhsetwar AP: Effects of serotonin on spontaneous ovulation: A theory for the dual hypothalamic control of ovulation. Acta Endocrinol (Copenh) 1971;68:334–344.
14.
Morello H, Caligaris L, Haymal B, Taleisnik S: Inhibition of proestrous LH surge and ovulation in rats evoked by stimulation of the medial raphe nucleus involves a GABA-mediated mechanism. Neuroendocrinology 1989;50:81–87.
15.
Tanaka E, Baba N, Toshida K, Suzuki K: Evidence for 5-HT2 receptor involvement in the stimulation of preovulatory LH and prolactin release and ovulation in normal cycling rats. Life Sci 1993;52:669–676.
16.
Dow RC, Williams BC, Bennie J, Carroll S, Fink G: A central 5-HT2 receptor mechanism plays a key role in the proestrous surge of luteinizing hormone in the rat. Psychoneuroendocrinology 1994;19:395–399.
17.
Justo SN, Rossano GL, Szwarcfarb B, Rubio MC, Moguilevsky JA: Effect of serotoninergic system on FSH secretion in male and female rats: Evidence for stimulatory and inhibitory actions. Neuroendocrinology 1989;50:382–386.
18.
Blum I, Nessiel L, David A, Graff E, Harsat A, Weissglass L, Gabbay U, Sulkes J, Yerushalmy Y, Vered Y: Plasma neurotransmitter profile during different phases of the ovulatory cycle. J Clin Endocrinol Metab 1992;75:924–929.
19.
Arendash GW, Gallo RV: Serotonin involvement in the inhibition of episodic luteinizing hormone release during electrical stimulation of the midbrain dorsal raphe nucleus in ovariectomized rats. Endocrinology 1978;102:1199–1206.
20.
Schneider HPG, McCann SM: Mono- and indolamines and control of LH secretion. Endocrinology 1970;86:1127–1130.
21.
Johnson MD, Crowley WR: Acute effects of estradiol on circulating luteinizing hormone and prolactin concentrations and on serotonin turnover in individual brain nuclei. Endocrinology 1983;113:1935–1941.
22.
Walker RF: Quantitative and temporal aspects of serotonin’s facilitatory action on phasic secretion of luteinizing hormone in female rats. Neuroendocrinology 1983;6:468–474.
23.
Meyer DC, Eadens DJ: The role of endogenous serotonin in phasic LH release. Brain Res Bull 1985;15:283–285.
24.
Goudreau JL, Wagner EJ, Lookingland KJ, Moore KE: Gamma-aminobutyric acid receptor-mediated regulation of periventricular-hypophysial dopaminergic neurons: possible role in mediating stress- and 5-hydroxytryptamine-induced decreases in neuronal activity. J Pharmacol Exp Ther 1994;271:1000–1006.
25.
Lawlor BA, Sunderland T, Hill JL, Mellow AM, Molchan SE, Mueller EA, Jacobsen FM, Murphy DL: Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects. Psychiatry Res 1989;29:1–10.
26.
Gonzales GF, Carrillo C: Blood serotonin levels in postmenopausal women: Effects of age and serum oestradiol levels. Maturitas 1993;17:23–29.
27.
Guicheney P, Leger D, Barrat J, Trevoux R, De Lignieres B, Roques P, Garnier JP, Boyer P, Grenier J, Dreux C: Platelet serotonin content and plasma tryptophan in peri- and postmenopausal women: Variations with plasma oestrogen levels and depressive symptoms. Eur J Clin Invest 1988;18:297–304.
28.
Di Sciullo A, Bluet-Pajot MT, Mounier F, Oliver C, Schmidt B, Kordon C: Changes in anterior pituitary hormone levels after serotonin 1A receptor stimulation. Endocrinology 1990;127:567–572.
29.
Mannisto PT, Tuominen RK: Further studies of serotonergic activity in the regulation of the cold stimulated thyrotropin secretion in male rats. Pharmacol Toxicol 1988;63:65–69.
30.
Toivonen M, Mannisto PT: Complex actions of serotonergic agonists on cold-stimulated TSH secretion in male rats. Eur J Pharmacol 1990;180:91–102.
31.
Fukuda H, Mori M, Ohshima K, Kobayashi I: The role of central serotoninergic and noradrenergic neurons in the regulation of nyctohemeral rhythm of plasma thyrotropin. J Endocrinol Invest 1980;3:243–249.
32.
Gerasimov G, Chernova T, Goncharov N: Monoamine regulation of prolactin and TSH secretion in hypothyroidism. Acta Med Austr 1992;19(suppl 1):86–88.
33.
Abrahamson MJ, Wormald PJ, Millar RP: Neuroendocrine regulation of thyrotropin release in cultured human pituitary cells. J Clin Endocrinol Metab 1987;65:1159–1163.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.